KatherineJWalshMD
Hematology • Nashville, TNAssociate Professor of Clinical Internal Medicine and Clerkship Director for the third year medical student Inpatient IM Clerkship, Ohio State University College of Medicine
Dr. Walsh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 The Vanderbilt Clinic
Nashville, TN 37232Phone+1 615-322-3000
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
University of FloridaResidency, Internal Medicine, 2004 - 2007- University of Florida College of MedicineClass of 2004
Certifications & Licensure
TN State Medical License 2021 - 2025
OH State Medical License 2011 - 2021
NC State Medical License 2008 - 2012
GA State Medical License 2007 - 2011- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Publications & Presentations
PubMed
- 431 citationsGenetic heterogeneity of diffuse large B-cell lymphomaJenny Zhang, Vladimir Grubor, Cassandra Love, Anjishnu Banerjee, Kristy L. Richards
Proceedings of the National Academy of Sciences of the United States of America. 2013-01-22 - 209 citationsSafety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation ph...Jean Pierre J. Issa, Gail J. Roboz, David A. Rizzieri, Elias J. Jabbour, Wendy Stock
The Lancet. Oncology. 2015-09-01 - 42 citationsDecitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, Jessica N Hofstetter, Alison Walker
Blood. 2015-04-23
Abstracts/Posters
- Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...Katherine J. Walsh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...Katherine J. Walsh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Katherine J. Walsh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
